Determine the necessary mass, volume, or concentration for preparing a solution.
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
BAY 2666605 is an orally active PDE3A and PDE3B inhibitor with IC 50 s of 87 nM and 50 nM, respectively. BAY 2666605 is a PDE3A-SLFN12 complex inducer (WO2019025562A1; example 135)
In Vitro
BAY 2666605 (example 135) has anticancer effects, potently inhibit brain cancer(especially glioma, more specifically glioblastoma, astrocytoma), breast cancer (especially ductal carcinoma and adenocarcinoma), cervical cancer, AML(especially erythroleucemia), lung cancer(especially NSCLC adenocarcinoma and SCLC), skin cancer(especially melanoma), oesophagus cancer (especially squamous cell carcinoma), ovarian cancer, (especially teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BAY 2666605 (5 mg/kg; p.o; twice daily) teatment shows anti-tumor efficacy in murine xenotransplantation models of human cancer . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:PDE3A 87 nM (IC 50 ) PDE3B 50 nM (IC 50 )
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubilità | DMSO : 250 mg/mL (709.66 mM; Need ultrasonic) |
|---|